PROCEPT BioRobotics Corporation
PRCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.10 | -3.04 | -0.41 | -2.95 |
| FCF Yield | -2.47% | -6.73% | -4.50% | -5.30% |
| EV / EBITDA | -48.10 | -18.37 | -21.89 | -16.49 |
| Quality | ||||
| ROIC | -20.01% | -30.14% | -31.39% | -17.37% |
| Gross Margin | 61.07% | 52.17% | 49.44% | 46.02% |
| Cash Conversion Ratio | 1.09 | 1.02 | 0.92 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.11% | 58.08% | 113.42% | 77.45% |
| Free Cash Flow Growth | 22.21% | -60.43% | -43.35% | -19.25% |
| Safety | ||||
| Net Debt / EBITDA | 3.09 | 1.81 | 1.86 | 4.90 |
| Interest Coverage | -23.09 | -27.33 | -15.57 | -9.32 |
| Efficiency | ||||
| Inventory Turnover | 1.56 | 1.64 | 1.33 | 1.42 |
| Cash Conversion Cycle | 328.43 | 276.77 | 258.61 | 265.35 |